Novartis (NVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Steve Scala from ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Novartis AG (NVS) reports a strong quarter with significant sales increases across key products and a record $6 billion in ...

Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis is scheduled to report results for ... KEY DRUGS: Early breast-cancer treatment Kisqali, immunology drug Cosentyx, neuroscience medicine Kesimpta and cardiovascular drug Entresto--the ...

Revenue from cancer medicine Kisqali and closely watched prostate cancer drug Pluvicto also slightly exceeded expectations. Novartis is focused on growth after years of constant change ...

Sales of Novartis' CDK4/6 inhibitor Kisqali (ribociclib) were $787 million in Q3 2024, up 40 percent from Q3 2023. The agent, ...